Zoekresultaten - 1 result
Low hepatitis C prevalence in Belgium: implications for treatment reimbursement and scale up.
to estimate the budgetary impact of reimbursement of direct-acting antivirals (DAA s). In Belgium, the restricted reimbursement criteria are mainly guided by regional seroprevalence estimates of 0.87% ...